| Naslov: | Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer : updated analysis of the observational GioTag study |
|---|
| Avtorji: | ID Hochmair, Maximilian J (Avtor)
ID Morabito, Alessandro (Avtor)
ID Hao, Desiree (Avtor)
ID Yang, Cheng-Ta (Avtor)
ID Soo, Ross A (Avtor)
ID Yang, James C-H (Avtor)
ID Gucalp, Rasim (Avtor)
ID Halmos, Balazs (Avtor)
ID Wang, Lara (Avtor)
ID Märten, Angela (Avtor)
ID Čufer, Tanja, Klinika Golnik, Medicinska fakulteta UL (Avtor) |
|---|
| Datoteke: |  PDF - Predstavitvena datoteka, prenos (1,58 MB)
MD5: AE826F62EC54CB83F71667FE803EEB71
PDF - Priloga, prenos (1,10 MB)
MD5: 501E9A968487DEB2D03082EAB847B278
 URL - Izvorni URL, za dostop obiščite https://www.futuremedicine.com/doi/full/10.2217/fon-2019-0346
|
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.01 - Izvirni znanstveni članek |
|---|
| Organizacija: |  UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
|
|---|
| Povzetek: | Aims: Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received sequential afatinib/osimertinib in the real-world GioTag study. Patients & methods: Patients had T790M-positive disease following first-line afatinib and received osimertinib treatment (n = 203). Primary outcome was TTF. The OS analysis was exploratory. Results: Median OS was 41.3 months (90% CI: 36.8-46.3) overall and 45.7 months (90% CI: 45.3-51.5) in patients with Del19-positive tumors (n = 149); 2-year survival was 80 and 82%, respectively. Updated median TTF with afatinib and osimertinib was 28.1 months (90% CI: 26.8-30.3). Conclusion: Sequential afatinib/osimertinib was associated with encouraging OS/TTF in patients with EGFR T790M-positive non-small-cell lung cancer, especially in patients with Del19-positive tumors. |
|---|
| Ključne besede: | non-small cell lung carcinoma - therapy, drug therapy, afatinib, osimertinib, GioTag study |
|---|
| Status publikacije: | Objavljeno |
|---|
| Verzija publikacije: | Objavljena publikacija |
|---|
| Kraj izida: | Velika Britanija |
|---|
| Založnik: | Future Medicine Ltd |
|---|
| Leto izida: | 2019 |
|---|
| Št. strani: | str. 2905-2914 |
|---|
| Številčenje: | Vol. 15, iss. 25 |
|---|
| PID: | 20.500.12556/DiRROS-12417  |
|---|
| UDK: | 616.2 |
|---|
| ISSN pri članku: | 1744-8301 |
|---|
| DOI: | 10.2217/fon-2019-0346 |
|---|
| COBISS.SI-ID: | 2048610929 |
|---|
| Avtorske pravice: | © 2019 Maximilian J Hochmair |
|---|
| Opomba: | Nasl. z nasl. zaslona;
Soavtorica iz Slovenije: Tanja Cufer;
Opis vira z dne 10. 1. 2020;
|
|---|
| Datum objave v DiRROS: | 11.09.2020 |
|---|
| Število ogledov: | 1816 |
|---|
| Število prenosov: | 1371 |
|---|
| Metapodatki: |    |
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
